StockNews.AI
IBO
StockNews.AI
18 hrs

Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue

1. IBO received patent No. 12,357,584 B2 for controlling infectious diseases. 2. The patent enhances IBO’s 3F™ technology with potential antibacterial applications. 3. Infectious disease market expected to grow significantly from $21.7B in 2024 to $34B in 2023. 4. IBO CEO emphasizes commitment to innovative healthcare solutions and market partnerships. 5. The patent supports disinfection against pathogens like E. coli, MRSA, and influenza.

5m saved
Insight
Article

FAQ

Why Bullish?

The granted patent provides IBO exclusive market rights, potentially boosting future revenue streams. Similar biotech patent approvals have historically corresponded with stock price surges.

How important is it?

The patent is a significant development for IBO, underlining its growth trajectory in the lucrative healthcare sector. The successful commercialization of patented technology could lead to substantial market interest and investor confidence.

Why Long Term?

Patent protection lasts until 2038, allowing extended time for market development and sales growth, similar to other biotech advancements leading to sustained stock value increases.

Related Companies

MODNNVTACRIS
HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO’s 3F™ technology platform. This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by plants, with potential application as an antibacterial or antiviral agent. This patent will expire on December 7, 2038. This expands Impact Biomedical’s 3F™ patent estate which includes insect repellent compositions and anti-microbial applications in the United States and other countries. It also further demonstrates IBO’s commitment to discovering, developing, and patenting unique technologies to meet unmet needs in human healthcare. These compositions and formulations have unique antimicrobial and antiviral properties. The compositions can be formulated to treat or limit the occurrence of various diseases and to kill and/or be used as a disinfectant against various microbes, pathogens, and the like. Potential applications include killing microbes as a disinfectant and to be administered to a patient to treat an infectious disease condition. The composition has potential effectiveness against various pathogens including but not limited to E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis. Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, continue to pose significant global health challenges, driving demand for new offerings and solutions in both established and developing regions worldwide. The worldwide infectious disease market is projected to grow from $21.7B in 2024 to $34B in 2023, representing a CAGR of 5.77% (source: Infectious Disease Market – Global Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032 I Data Bridge Market Research). Upon notification of the patent issue, IBO CEO Frank Heuszel said, “This is another demonstration of success with our business model delivering new unique proprietary technology with the potential to address unmet needs in human healthcare. We continue discussions with potential partners to move 3F™ towards the market in the US and other countries worldwide.” About IBO:Impact Biomedical Inc. (IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. Safe Harbor Disclosure:This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date. Investor Relations:info@impactbiomedinc.com www.impactbiomedinc.com

Related News